Adlai Nortye (NASDAQ:ANL) Director Ping Ji Sells 5,000 Shares

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Director Ping Ji sold 5,000 shares of Adlai Nortye stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total value of $83,150.00. Following the completion of the transaction, the director owned 131,667 shares of the company’s stock, valued at approximately $2,189,622.21. This trade represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Adlai Nortye Trading Down 2.0%

Shares of NASDAQ ANL traded down $0.32 during trading hours on Thursday, hitting $15.43. 66,283 shares of the company traded hands, compared to its average volume of 372,919. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55. The company’s 50 day moving average price is $13.89 and its 200 day moving average price is $11.96. Adlai Nortye Ltd. Sponsored ADR has a 12 month low of $0.88 and a 12 month high of $17.25.

Analyst Upgrades and Downgrades

ANL has been the topic of several recent analyst reports. Jefferies Financial Group started coverage on shares of Adlai Nortye in a research note on Thursday, September 10th. They issued a “buy” rating and a $31.00 target price on the stock. Wall Street Zen downgraded shares of Adlai Nortye from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Adlai Nortye in a research report on Tuesday, September 8th. Cantor Fitzgerald began coverage on Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Adlai Nortye has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. SmartHarvest Portfolios LLC grew its holdings in Adlai Nortye by 8.5% during the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after acquiring an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Adlai Nortye during the first quarter worth $457,000. Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the second quarter valued at approximately $1,302,000. ADAR1 Capital Management LLC acquired a new position in Adlai Nortye during the first quarter worth approximately $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Adlai Nortye in the first quarter valued at $1,140,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.